Adapti, Inc.
Adapti, Inc. is a U.S.-based early-stage services company that has built an AI-driven software platform to analyze product data, social media signals, and audience behavior to identify the most effective influencers for a given product or brand. The company developed the Adapti platform internally beginning in 2021 and has used third-party AI tools such as ChatGPT, OpenAI, and Google AI to create a "data fingerprint" for products and companies. Management says the platform is intended to improve return on marketing spend by matching products with influencers and curated audiences, and it has been tested in live transactions supporting sales of Dermacia products. In addition to the AI platform, the company has sold licensed consumer products direct-to-consumer and has taken on outsourced programming work to generate limited income while deploying its technical staff.
Fiscal year 2025 · change from previous year
Development 2025–2025
Business
Share of revenueSoftware that analyzes product, company, and social data to identify influencers and optimize campaign ROI.
Licensed Dermacia skin care and healthcare products sold direct to consumers.
Programming and related outsourced work performed to generate limited service income.
Customers
Adapti's intended customer base includes brands and product owners that want to use influencer marketing and social media promotion more efficiently. The company also appears to support its own Dermacia product sales, which implies direct consumers are a current customer group for the licensed product line. Management specifically references Ballengee clients as a future use case for the platform, suggesting sports, entertainment, and talent-related clients are an important target segment. Because the platform is designed to improve ROI on promotional spend, customers are likely buying either campaign execution support or analytics that help them choose the right influencers and channels.
Buy influencer selection and campaign analytics to improve social media promotion efficiency and ROI.
Buy licensed skin care and healthcare products sold directly by the company.
Uses the platform and related services for social media opportunities and audience engagement.
Buy programming or project-based technical work while the platform is still early-stage.
Strategy
The company's core strategy is to turn the internally developed Adapti platform into a commercial tool for influencer selection, campaign optimization, and social-media-driven sales. Management is trying to leverage the platform across its own Dermacia product sales and, potentially, Ballengee client relationships to demonstrate practical use cases and build a monetizable data asset. A second strategic priority is to use the company's programming capabilities to take on outsourced work and keep personnel deployed while the platform matures. Longer term, the company is attempting to build a differentiated AI marketing capability, but success depends on proving that the platform can generate measurable ROI and attract repeat customers.
The platform has not yet generated revenue, so proving commercial demand is essential to turning development spend into a business.
Better data and feedback loops should improve influencer matching and campaign ROI, which is the platform's core value proposition.
Dependence on Dermacia limits scale, so broader client adoption is needed for the platform to matter economically.
Geography
Adapti is headquartered in the United States and the available disclosures do not provide a country-by-country revenue split. The business appears to be primarily U.S.-oriented, given its SEC reporting, U.S. consumer product sales, and references to U.S. AI regulation and social media platforms. Its platform depends on third-party AI tools and cloud infrastructure, which can create cross-border technology and compliance exposure even if end customers are domestic. The company also faces regulatory developments in the United States, the European Union, and other jurisdictions because its product relies on AI and data collection.
Risks
Adapti is an early-stage company with limited operating history, so investors have little evidence that the platform can become a durable revenue engine. The business depends on consumer tastes, social media trends, and the popularity of the talent or brands it represents, which makes demand volatile and hard to forecast. Because the platform relies on AI, social data, and cloud infrastructure, it faces cybersecurity, data-loss, intellectual property, and regulatory risks that could raise costs or interrupt operations. Reputation risk is also important because adverse publicity around management, clients, or partners could damage relationships and reduce the company's ability to win new business. The company also appears to have concentration risk around a small number of products, clients, and strategic relationships, which increases execution risk if any one initiative underperforms.
- Limited operating history and unproven monetizationImpact: HighLikelihood: High
The company has spent on development but has not yet generated revenue from Adapti, so the platform's commercial success remains uncertain.
Exposure: Platform commercialization and overall enterprise value
- AI regulatory and legal riskImpact: HighLikelihood: Medium
Governments in the U.S., EU, and elsewhere are considering or adopting AI rules that could impose compliance burdens or limit certain uses.
Exposure: Adapti platform development and deployment
- Cybersecurity and data protection riskImpact: HighLikelihood: Medium
The platform processes proprietary, confidential, and personal data and depends on third-party hosting and cloud providers.
Exposure - Consumer preference and brand reputation riskImpact: MediumLikelihood: Medium
Demand for services and content is sensitive to changing tastes and publicity around the company or its partners.
Exposure: Marketing and client relationships
- Intellectual property and competitive technology riskImpact: MediumLikelihood: Medium
Competitors with greater resources may build better tools, and some platform elements may not be fully protectable.
Exposure: Technology differentiation
Accounting
Judgemental itemsThe company spent about $500,000 developing Adapti, so whether costs are expensed or capitalized affects reported earnings and asset values.
Impact: Could materially affect operating loss and balance sheet presentation
Future arrangements may include software access, campaign services, and product sales, each with different recognition patterns.
Impact: Affects timing of revenue and gross margin
If the platform does not generate expected revenue, capitalized development or related intangibles may need write-downs.
Impact: Could create non-cash charges and reduce equity
Dermacia sales may be influenced by promotions, launches, and social media campaigns.
Impact: Makes quarterly comparisons less stable
Similar listed companies
Publicly listed companies with a comparable business focus.
Amplitude, Inc.
AMPL · Services-Prepackaged Software
Domo, Inc
HUCK · Services-Prepackaged Software
Angi Inc.
ANGI · Services-Advertising
Avai Bio, Inc.
AVAI · Services-Computer Processing & Data Preparation
Spectral AI, Inc.
MDAIW · Surgical & Medical Instruments & Apparatus
Absci Corp
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
Last updated: 24/09/2026